Skip to main page content

Case Reports

. 2013 Dec;69(6):1070-2.

doi: 10.1016/j.jaad.2013.02.032.

Intralesional interferon alfa-2b for refractory, recurrent squamous cell carcinoma of the face

Allison Hanlon¹, June Kim, David J Leffell

Affiliations

Affiliation

¹ Department of Dermatology, Section of Cutaneous Oncology and Dermatologic Surgery, Yale University School of Medicine, New Haven, Connecticut. Electronic address: allison.hanlon@yale.edu.

PMID: 24238178
DOI: 10.1016/j.jaad.2013.02.032

Case Reports

Intralesional interferon alfa-2b for refractory, recurrent squamous cell carcinoma of the face

Allison Hanlon et al. J Am Acad Dermatol. 2013 Dec.

. 2013 Dec;69(6):1070-2.

doi: 10.1016/j.jaad.2013.02.032.

Authors

Allison Hanlon¹, June Kim, David J Leffell

Affiliation

¹ Department of Dermatology, Section of Cutaneous Oncology and Dermatologic Surgery, Yale University School of Medicine, New Haven, Connecticut. Electronic address: allison.hanlon@yale.edu.

PMID: 24238178
DOI: 10.1016/j.jaad.2013.02.032

No abstract available

PubMed Disclaimer

Similar articles

Treatment of aggressive basal cell carcinoma with intralesional interferon: evaluation of efficacy by Mohs surgery.
Stenquist B, Wennberg AM, Gisslén H, Larkö O. Stenquist B, et al. J Am Acad Dermatol. 1992 Jul;27(1):65-9. doi: 10.1016/0190-9622(92)70158-c. J Am Acad Dermatol. 1992. PMID: 1619079
Therapeutic efficacy of interferon alfa-2a and 13-cis-retinoic acid in recurrent angiosarcoma of the head.
Spieth K, Gille J, Kaufmann R. Spieth K, et al. Arch Dermatol. 1999 Sep;135(9):1035-7. doi: 10.1001/archderm.135.9.1035. Arch Dermatol. 1999. PMID: 10490107 No abstract available.
Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma.
Brewster AM, Lee JJ, Clayman GL, Clifford JL, Reyes MJ, Zhou X, Sabichi AL, Strom SS, Collins R, Meyers CA, Lippman SM. Brewster AM, et al. J Clin Oncol. 2007 May 20;25(15):1974-8. doi: 10.1200/JCO.2006.05.9873. J Clin Oncol. 2007. PMID: 17513803 Clinical Trial.
Topical and intralesional treatment of nonmelanoma skin cancer: efficacy and cost comparisons.
Chitwood K, Etzkorn J, Cohen G. Chitwood K, et al. Dermatol Surg. 2013 Sep;39(9):1306-16. doi: 10.1111/dsu.12300. Epub 2013 Aug 5. Dermatol Surg. 2013. PMID: 23915332 Review.
Intralesional agents in the management of cutaneous malignancy: a review.
Good LM, Miller MD, High WA. Good LM, et al. J Am Acad Dermatol. 2011 Feb;64(2):413-22. doi: 10.1016/j.jaad.2009.12.013. Epub 2010 Mar 23. J Am Acad Dermatol. 2011. PMID: 20334952 Review.

See all similar articles

Cited by

Intralesional Treatments for Invasive Cutaneous Squamous Cell Carcinoma.
Baeza-Hernández G, Cañueto J. Baeza-Hernández G, et al. Cancers (Basel). 2023 Dec 28;16(1):158. doi: 10.3390/cancers16010158. Cancers (Basel). 2023. PMID: 38201585 Free PMC article. Review.
Advances in cutaneous squamous cell carcinoma.
Winge MCG, Kellman LN, Guo K, Tang JY, Swetter SM, Aasi SZ, Sarin KY, Chang ALS, Khavari PA. Winge MCG, et al. Nat Rev Cancer. 2023 Jul;23(7):430-449. doi: 10.1038/s41568-023-00583-5. Epub 2023 Jun 7. Nat Rev Cancer. 2023. PMID: 37286893 Review.
Intratumoural administration and tumour tissue targeting of cancer immunotherapies.
Melero I, Castanon E, Alvarez M, Champiat S, Marabelle A. Melero I, et al. Nat Rev Clin Oncol. 2021 Sep;18(9):558-576. doi: 10.1038/s41571-021-00507-y. Epub 2021 May 18. Nat Rev Clin Oncol. 2021. PMID: 34006998 Free PMC article. Review.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations
Medical
- Genetic Alliance
- MedlinePlus Health Information